Genomics is stepping up to buy Scale Biosciences and its single-cell profiling solutions, with plans to implement them within ...

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, ...

The FDA has denied Stealth BioTherapeutics’ request to reconsider its complete response letter, leaving the fate of the biotech and its investigational treatment for an ultrarare genetic disease ...